R-848 triggers the expression of TLR7/8 and suppresses HIV replication in monocytes

BMC Infectious Diseases

Volumn 12, Issue , 2012, Pages

  Nian, Hua ^a   Geng, Wen Qing ^a   Cui, Hua Lu ^a   Bao, Ming jia ^b   Zhang, Zi ning ^a   Zhang, Min ^a   Pan, Ying ^a   Hu, Qing Hai ^a   Shang, Hong ^a  

^a CHINA MEDICAL UNIVERSITY   (China)

^b SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

Hiv; Monocytes; R 848; Toll like receptor

Indexed keywords

INTERLEUKIN 12P40; MESSENGER RNA; RESIQUIMOD; TOLL LIKE RECEPTOR 7; TOLL LIKE RECEPTOR 8; TUMOR NECROSIS FACTOR ALPHA; IMIDAZOLE DERIVATIVE; IMMUNOLOGIC FACTOR;

ADULT; ARTICLE; CELL ISOLATION; CELL STIMULATION; CHINA; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG MECHANISM; FEMALE; GENE EXPRESSION; HUMAN; HUMAN CELL; HUMAN CELL CULTURE; HUMAN IMMUNODEFICIENCY VIRUS; MALE; MONOCYTE; NONHUMAN; PROTEIN EXPRESSION; SIGNAL TRANSDUCTION; VIRUS INHIBITION; VIRUS REPLICATION; BIOSYNTHESIS; CELL CULTURE; GENE EXPRESSION PROFILING; GROWTH, DEVELOPMENT AND AGING; IMMUNOLOGY; MIDDLE AGED; VIROLOGY;

ADULT; CELLS, CULTURED; CHINA; FEMALE; GENE EXPRESSION PROFILING; HIV; HUMANS; IMIDAZOLES; IMMUNOLOGIC FACTORS; MALE; MIDDLE AGED; MONOCYTES; TOLL-LIKE RECEPTOR 7; TOLL-LIKE RECEPTOR 8; VIRUS REPLICATION;

EID: 84855756265     PISSN: None     EISSN: 14712334     Source Type: Journal    
DOI: 10.1186/1471-2334-12-5     Document Type: Article

References (47)

1. Levy JA. The importance of the innate immune system in controlling HIV infection and disease. Trends in immunology 2001, 22:312-316. 10.1016/S1471-4906(01)01925-1, 11377290.
2. Lehner T. Innate and adaptive mucosal immunity in protection against HIV infection. Vaccine 2003, 21(Suppl 2):S68-S76.
3. Siegal FP, Spear GT. Innate immunity and HIV. AIDS (London, England) 2001, Suppl 5(5):127-13.
4. Takeda K, Kaisho T, Akira S. Toll-like receptors. Annu Rev Immunol 2003, 21:335-376. 10.1146/annurev.immunol.21.120601.141126, 12524386.
5. Barton GM. Viral recognition by Toll-like receptors. Semin Immunol 2007, 19:33-40. 10.1016/j.smim.2007.01.003, 17336545.
6. Pasare C, Medzhitov R. Toll-like receptors: linking innate and adaptive immunity. Adv Exp Med Biol 2005, 560:11-18. 10.1007/0-387-24180-9_2, 15932016.
7. Kumar H, Kawai T, Akira S. Toll-like receptors and innate immunity. Biochem Biophys Res Commun 2009, 388:621-625. 10.1016/j.bbrc.2009.08.062, 19686699.
8. Akira S, Uematsu S, Takeuchi O. Pathogen recognition and innate immunity. Cell 2006, 124:783-801. 10.1016/j.cell.2006.02.015, 16497588.
9. Alter G, Suscovich TJ, Teigen N, Meier A, Streeck H, Brander C, Altfeld M. Single-stranded RNA derived from HIV-1 serves as a potent activator of NK cells. J Immunol 2007, 178:7658-7666.
10. Song Y, Zhuang Y, Zhai S, Huang D, Zhang Y, Kang W, Li X, Liu Q, Yu Q, Sun Y. Increased expression of TLR7 in CD8(+) T cells leads to TLR7-mediated activation and accessory cell-dependent IFN-gamma production in HIV type 1 infection. AIDS research and human retroviruses 2009, 25:1287-1295. 10.1089/aid.2008.0303, 19954299.
11. Oh DY, Baumann K, Hamouda O, Eckert JK, Neumann K, Kucherer C, Bartmeyer B, Poggensee G, Oh N, Pruss A, et al. A frequent functional toll-like receptor 7 polymorphism is associated with accelerated HIV-1 disease progression. AIDS (London, England) 2009, 23:297-307.
12. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science (New York, NY) 2004, 303:1529-1531.
13. Heil F, Hemmi H, Hochrein H, Ampenberger F, Kirschning C, Akira S, Lipford G, Wagner H, Bauer S. Species-specific recognition of single-stranded RNA via toll-like receptor 7 and 8. Science (New York, NY) 2004, 303:1526-1529.
14. Hiscott J, Kwon H, Genin P. Hostile takeovers: viral appropriation of the NF-kappaB pathway. J Clin Invest 2001, 107:143-151. 10.1172/JCI11918, 199181, 11160127.
15. Bekeredjian-Ding I, Roth SI, Gilles S, Giese T, Ablasser A, Hornung V, Endres S, Hartmann G. T cell-independent, TLR-induced IL-12p70 production in primary human monocytes. J Immunol 2006, 176:7438-7446.
16. Bonizzi G, Karin M. The two NF-kappaB activation pathways and their role in innate and adaptive immunity. Trends Immunol 2004, 25:280-288. 10.1016/j.it.2004.03.008, 15145317.
17. Hartmann G, Krieg AM. CpG DNA and LPS induce distinct patterns of activation in human monocytes. Gene Therapy 1999, 6:893-903. 10.1038/sj.gt.3300880, 10505115.
18. Ellery PJ, Tippett E, Chiu YL, Paukovics G, Cameron PU, Solomon A, Lewin SR, Gorry PR, Jaworowski A, Greene WC, et al. The CD16+ monocyte subset is more permissive to infection and preferentially harbors HIV-1 in vivo. J Immunol 2007, 178:6581-6589.
19. Jurk M, Heil F, Vollmer J, Schetter C, Krieg AM, Wagner H, Lipford G, Bauer S. Human TLR7 or TLR8 independently confer responsiveness to the antiviral compound R-848. Nat Immunol 2002, 3:499.
20. Zhu T, Muthui D, Holte S, Nickle D, Feng F, Brodie S, Hwangbo Y, Mullins JI, Corey L. Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy. J Virol 2002, 76:707-716. 10.1128/JVI.76.2.707-716.2002, 136806, 11752161.
21. Perry CM, Lamb HM. Topical imiquimod: a review of its use in genital warts. Drugs 1999, 58:375-390. 10.2165/00003495-199958020-00017, 10473026.
22. Gibson SJ, Imbertson LM, Wagner TL, Testerman TL, Reiter MJ, Miller RL, Tomai MA. Cellular requirements for cytokine production in response to the immunomodulators imiquimod and S-27609. J Interferon Cytokine Res 1995, 15:537-545. 10.1089/jir.1995.15.537, 7553223.
23. Pockros PJ, Guyader D, Patton H, Tong MJ, Wright T, McHutchison JG, Meng TC. Oral resiquimod in chronic HCV infection: safety and efficacy in 2 placebo-controlled, double-blind phase IIa studies. J Hepatol 2007, 47:174-182. 10.1016/j.jhep.2007.02.025, 17532523.
24. Schlaepfer E, Audige A, Joller H, Speck RF. TLR7/8 triggering exerts opposing effects in acute versus latent HIV infection. J Immunol 2006, 176:2888-2895.
25. Mikovits JA, Lohrey NC, Schulof R, Courtless J, Ruscetti FW. Activation of infectious virus from latent human immunodeficiency virus infection of monocytes in vivo. J Clin Invest 1992, 90:1486-1491. 10.1172/JCI116016, 443195, 1401081.
26. Sonza S, Mutimer HP, Oelrichs R, Jardine D, Harvey K, Dunne A, Purcell DF, Birch C, Crowe SM. Monocytes harbour replication-competent, non-latent HIV-1 in patients on highly active antiretroviral therapy. AIDS (London, England) 2001, 15:17-22.
27. Almodovar S, Del CCM, Maldonado IM, Villafane R, Abreu S, Melendez I, Dominguez C, Cuevas W, Collins TM, Lorenzo E. HIV-1 infection of monocytes is directly related to the success of HAART. Virology 2007, 369:35-46. 10.1016/j.virol.2007.07.010, 17707072.
28. Naif HM, Li S, Alali M, Chang J, Mayne C, Sullivan J, Cunningham AL. Definition of the stage of host cell genetic restriction of replication of human immunodeficiency virus type 1 in monocytes and monocyte-derived macrophages by using twins. J Virol 1999, 73:4866-4881. 112530, 10233948.
29. Triques K, Stevenson M. Characterization of restrictions to human immunodeficiency virus type 1 infection of monocytes. J Virol 2004, 78:5523-5527. 10.1128/JVI.78.10.5523-5527.2004, 400363, 15113933.
30. Lambotte O, Taoufik Y, de Goer MG, Wallon C, Goujard C, Delfraissy JF. Detection of infectious HIV in circulating monocytes from patients on prolonged highly active antiretroviral therapy. J Acquired Immune Deficiency Syndromes (1999) 2000, 23:114-119.
31. Koyama S, Ishii KJ, Kumar H, Tanimoto T, Coban C, Uematsu S, Kawai T, Akira S. Differential role of TLR- and RLR-signaling in the immune responses to influenza A virus infection and vaccination. J Immunol 2007, 179:4711-4720.
32. Reis e Sousa C. Activation of dendritic cells: translating innate into adaptive immunity. Current Opin Immunol 2004, 16:21-25.
33. Iwasaki A, Medzhitov R. Toll-like receptor control of the adaptive immune responses. Nat Immunol 2004, 5:987-995. 10.1038/ni1112, 15454922.
34. Aukrust P, Muller F, Lien E, Nordoy I, Liabakk NB, Kvale D, Espevik T, Froland SS. Tumor necrosis factor (TNF) system levels in human immunodeficiency virus-infected patients during highly active antiretroviral therapy: persistent TNF activation is associated with virologic and immunologic treatment failure. J Infect Dis 1999, 179:74-82. 10.1086/314572, 9841825.
35. Kedzierska K, Crowe SM. Cytokines and HIV-1: interactions and clinical implications. Antivir Chem Chemother 2001, 12:133-150.
36. Khanna KV, Yu XF, Ford DH, Ratner L, Hildreth JK, Markham RB. Differences among HIV-1 variants in their ability to elicit secretion of TNF-alpha. J Immunol 2000, 164:1408-1415.
37. Bergamini A, Faggioli E, Bolacchi F, Gessani S, Cappannoli L, Uccella I, Demin F, Capozzi M, Cicconi R, Placido R, et al. Enhanced production of tumor necrosis factor-alpha and interleukin-6 due to prolonged response to lipopolysaccharide in human macrophages infected in vitro with human immunodeficiency virus type 1. J Infect Dis 1999, 179:832-842. 10.1086/314662, 10068578.
38. Rimaniol AC, Boussin FD, Dormont D, Bach JF, Zavala F. Mechanisms of downmodulation and release of tumour necrosis factor receptor induced by human immunodeficiency virus type 1 in human monocytes. Cytokine 1997, 9:9-18. 10.1006/cyto.1996.0130, 9067091.
39. Merrill JE, Koyanagi Y, Chen IS. Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol 1989, 63:4404-4408. 251058, 2789293.
40. Zembala M, Pryjma J, Plucienniczak A, Szczepanek A, Jasinski M, Ruggiero I, Piselli P, Colizzi V. Interaction of HIV-1 gp120 molecule fragments with human monocytes: different requirements for tumor necrosis factor-alpha and IL-6 production. Clin Immunol Immunopathol 1995, 75:131-139. 10.1006/clin.1995.1062, 7704970.
41. Catalfamo M, Di Mascio M, Hu Z, Srinivasula S, Thaker V, Adelsberger J, Rupert A, Baseler M, Tagaya Y, Roby G, et al. HIV infection-associated immune activation occurs by two distinct pathways that differentially affect CD4 and CD8 T cells. Proc Natl Acad Sci USA 2008, 105:19851-19856. 10.1073/pnas.0810032105, 2596741, 19060209.
42. Innocenti P, Ottmann M, Morand P, Leclercq P, Seigneurin JM. HIV-1 in blood monocytes: frequency of detection of proviral DNA using PCR and comparison with the total CD4 count. AIDS Res Human Retroviruses 1992, 8:261-268.
43. Hart OM, Athie-Morales V, O'Connor GM, Gardiner CM. TLR7/8-mediated activation of human NK cells results in accessory cell-dependent IFN-gamma production. J Immunol 2005, 175:1636-1642.
44. Akira S, Takeda K. Toll-like receptor signalling. Nat Reviews 2004, 4:499-511.
45. Miettinen M, Sareneva T, Julkunen I, Matikainen S. IFNs activate toll-like receptor gene expression in viral infections. Genes and Immunity 2001, 2:349-355. 10.1038/sj.gene.6363791, 11607792.
46. Grossman Z, Meier-Schellersheim M, Paul WE, Picker LJ. Pathogenesis of HIV infection: what the virus spares is as important as what it destroys. Nat Med 2006, 12:289-295. 10.1038/nm1380, 16520776.
47. Lester RT, Yao XD, Ball TB, McKinnon LR, Kaul R, Wachihi C, Jaoko W, Plummer FA, Rosenthal KL. Toll-like receptor expression and responsiveness are increased in viraemic HIV-1 infection. AIDS (London, England) 2008, 22:685-694.